DOI: 10.55522/jmpas.V13I4.6597 **ISSN NO. 2320 – 7418**

International peer reviewed open access journal

Journal of Medical Pharmaceutical and Allied Sciences

Journal homepage: www.jmpas.com CODEN: JMPACO

Research article

Cutting-edge developments in acute myeloid leukaemia: innovations in diagnosis and treatment

Monalisha Pal*[1], Prerna Bhandari[2], Neelam[3], Nikita[3], Garima Pant[2], Avadhesh Tripathi[4]

[1] Department of Community Health Nursing, Sharda School of Nursing Science and Research, Greater Noida, Uttar Pradesh, India
[2] Department of Mental Health Nursing, Prakash Institute of Paramedical, Rehabilitation, Allied Medical Sciences, Greater Noida Uttar Pradesh, India
[3] Department of Obstetrics and Gynaecological Nursing, Prakash Institute of Paramedical, Rehabilitation, Allied Medical Sciences, GreaterNoida, Uttar Pradesh, India
[4] Department of Healthcare Projects: Extension for community Healthcare Outcomes, ECHO India, New Delhi., India

Corresponding author: Monalisha Pal, ✉ monalishapal845@gmail.com**, Orcid Id**: https://orcid.org/0000-0002-8734-3190

Department of Community Health Nursing, Sharda School of Nursing Science and Research, Greater Noida, Uttar Pradesh, India

Received - 30-06-2024**, Revised** - 17-07-2024, **Accepted** - 17-08-2024 **(DD-MM-YYYY)**

Refer This Article

Monalisha Pal, Prerna Bhandari, Neelam, Nikita, Garima Pant, Avadhesh Tripathi, 2024. Cutting-edge developments in acute myeloid leukaemia: innovations in diagnosis and treatment. Journal of medical pharmaceutical and allied sciences, V 13 - I 4, Pages - 6704 – 6708. Doi: https://doi.org/10.55522/jmpas.V13I4.6597.

ABSTRACT

Acute Myeloid Leukaemia (AML) is a fast-growing hematologic malignancy that is distinguished by the clonal proliferation of myeloid progenitors in bone marrow. Recent advances in molecular biology and genomic technology have altered the landscape of AML diagnosis and therapy, resulting in more tailored and successful therapeutic approaches. This study reviews recent innovations in the diagnosis and treatment of AML, focusing on genomic profiling, next-generation sequencing (NGS), and novel targeted therapies. Data was collected from recent clinical trials, peer-reviewed journals, and case studies. Comparative analysis was conducted to evaluate the efficacy of emerging diagnostic tools and treatments. NGS and MRD monitoring have greatly improved diagnosis accuracy and therapy customization. Targeted medicines have enhanced remission rates and decreased recurrence rates in individuals with certain genetic alterations. Immunotherapies have showed long-term efficacy and controllable safety profiles. Combining modern diagnostic technologies with customized medicines ushers in a new era of AML care, enhancing prognosis and quality of life. Ongoing research and clinical trials are critical for improving these therapies and expanding their advantages to a larger patient group.



Keywords: Acute Myeloid Leukaemia, Next-Generation Sequencing (NGS), Minimal Residual Disease, Targeted Therapy, Immunotherapy, CAR-T cells, Genetic Profiling.

INTRODUCTION

Acute Myeloid Leukaemia (AML) is a broad collection of hematologic malignancies with various genetic and molecular abnormalities. AML has long presented major diagnostic and therapy hurdles because to its fast development and complexity. However, recent technology developments have heralded a new age of precision medicine, with enhanced diagnostic accuracy and unique therapy alternatives. This review looks at the most recent advances in AML diagnosis and therapy, emphasizing their influence on clinical outcomes and future prospects in AML research.

Acute Myeloid Leukemia (AML) is a kind of malignancy that begins in the bone marrow and affects both blood and bone marrow cells. It is distinguished by the fast proliferation of aberrant white blood cells in the bone marrow, which interferes with the formation of normal blood cells. AML is the most prevalent acute leukemia in adults but rare in youngsters. This literature review examines many aspects of AML, including as epidemiology, pathogenesis, clinical presentation, diagnostic tools, therapy choices, and new research advances.

Pathophysiology

AML is caused by genetic abnormalities in hematopoietic stem cells, which result in uncontrolled proliferation and poor myeloid differentiation. The buildup of immature cells, known as blasts, in the bone marrow and peripheral circulation causes bone marrow failure. FLT3, NPM1, DNMT3A, and CEBPA are among the key genetic alterations associated with AML. The discovery of these mutations has been critical to understanding the illness and creating targeted therapeutics.

Clinical Presentation

Patients with AML may have nonspecific symptoms such as tiredness, fever, weight loss, and night sweats. Common symptoms include anaemia, thrombocytopenia (low platelet count), and neutropenia (low white blood cell count), which can cause pallor, bleeding, and an increased susceptibility to infections. A physical examination may indicate hepatosplenomegaly (enlarged liver and spleen) and lymphadenopathy (swollen lymph nodes).

Figure 1: Pathogenesis of Acute Myeloid Leukemia



Innovations in diagnosis

Next Generation Sequencing (NGS) and Genetic Profiling

Next-generation sequencing (NGS) has transformed the diagnostic approach to AML by allowing for detailed genomic profiling of leukemic cells. This method makes it easier to identify recurring genetic variants such FLT3, NPM1, and IDH1/2, which are important for risk assessment and tailored treatment planning [1]. The capacity to identify several mutations at the same time provides for a more in-depth understanding of the disease's genetic landscape, which informs therapy options and prognosis.

Minimum Residual Disease (MRD) Monitoring

MRD refers to the tiny number of leukemic cells that remain in the patient after therapy and may lead to recurrence. NGS has increased MRD detection sensitivity, enabling for the molecular diagnosis of residual illness [2]. (Early identification of MRD is crucial for evaluating treatment response, predicting recurrence, and making informed decisions regarding future therapeutic measures.

Flow cytometry and Immunophenotyping

Flow cytometry has been a key tool in AML diagnosis, allowing the discovery of particular cell surface markers that distinguish leukemic cells. Advanced Immunophenotyping approaches improve diagnosis accuracy by differentiating AML subtypes and measuring MRD [3, 4]. The combination of flow cytometry and genetic data improves risk categorization and treatment planning.

Digital pathology and artificial intelligence (AI).

Digital pathology, along with AI, has considerably increased the efficiency and accuracy of AML detection. AI algorithms examine histopathological pictures to identify morphological traits and patterns

that are suggestive of AML, assisting pathologists in establishing accurate diagnosis [5, 6]. These technologies enable remote consultations and second opinions, which improve diagnostic skills in a variety of healthcare contexts.

Epidemiology

AML incidence rises with age, with a median age of diagnosis of around 68 years. According to studies, incidence rates vary across the world and are impacted by genetic, environmental, and occupational variables. According to the American Cancer Society, AML affects around 4.3 per 100,000 people in the United States each year. Radiation exposure, certain chemicals such as benzene, smoking, and a history of other blood illnesses or genetic abnormalities all increase the risk of developing AML.

Figure 2: Epidemiology of Acute Myeloid Leukemia



Innovations in treatment

Targeted therapies

The discovery of particular genetic abnormalities in AML has resulted in the development of tailored treatments that block aberrant signaling pathways. FLT3 inhibitors like midostaurin and gilteritinib have shown remarkable effectiveness in patients with FLT3-mutated AML, boosting survival rates [7]. Similarly, IDH inhibitors such as ivosidenib and enasidenib target IDH1 and IDH2 mutations, respectively, providing novel therapy choices for individuals with these particular genetic changes [8].

Immunotherapy and antibody-drug conjugates (ADCs)

Immunotherapeutic techniques have emerged as viable therapy options for AML. Monoclonal antibodies, such gemtuzumab ozogamicin, target particular antigens on AML cells and deliver cytotoxic chemicals specifically to the cancer cells, reducing systemic toxicity [9] Furthermore, checkpoint inhibitors attempt to improve the immune system's ability to identify and destroy AML cells, and have shown promise in early-stage clinical studies [10].

CAR T cell Therapy

Chimeric antigen receptor T-cell (CAR-T) therapy is a breakthrough method to AML treatment. This tailored treatment entails genetically modifying a patient's T-cells to express receptors for AML-specific antigens, leading the immune system to attack cancer cells [11]. Although still in the experimental stage, CAR-T cell therapy has demonstrated encouraging outcomes in early-phase clinical studies and is being intensively researched for broader applicability in AML.

Epigenetic Modifiers and Hypo ethylating Agents

Epigenetic modifications play a crucial role in the pathogenesis of AML. Hypo ethylating agents such as azacitidine and decitabine have been shown too effective in older patients with AML who are not candidates for intensive chemotherapy [12]. These agents induce DNA hypo methylation, reactivating silenced tumour suppressor genes and promoting apoptosis of leukemic cells.

Combination Therapies and Personalized Medicine

The integration of genomic data into clinical practice has facilitated the development of personalized medicine approaches, combining targeted therapies, immunotherapies, and conventional chemotherapies based on individual patient profiles.[13]This approach aims to maximize therapeutic efficacy while minimizing adverse effects, ultimately improving patient outcomes.

Future Directions and Conclusion

The future of AML research and treatment continues to evolve rapidly, driven by ongoing advancements in technology and molecular biology. Precision medicine, AI-driven diagnostics, and innovative therapeutic approaches hold promise for further improving outcomes and quality of life for AML patients. Continued investment in research and clinical trials will be essential to translate these innovations into widespread clinical practice.

METHOD, RESULTS & DISCUSSION

Recent advances in the diagnosis and treatment of acute myeloid leukaemia (AML) have profoundly altered the landscape of patient care, providing fresh hope for better results. Innovations in diagnostic approaches, notably the use of next-generation sequencing

(NGS), have significantly improved AML diagnosis precision. NGS has enabled the discovery of previously undetected genetic mutations and epigenetic alterations, resulting in more accurate illness categorisation and personalised treatment methods. The use of these new genetic tools has also aided in the creation of tailored medicines for specific molecular defects, altering the therapeutic strategy. In terms of therapy, new drugs, such as FLT3 inhibitors, IDH inhibitors, and BCL-2 antagonists, have shown significant effectiveness in clinical studies. These targeted medicines, together with advances in immunotherapy such as CAR-T cell therapy and monoclonal antibodies, constitute a paradigm change in AML treatment, taking it beyond traditional chemotherapy. CAR-T cell therapy, in particular, has demonstrated encouraging outcomes in refractory or relapsed AML patients, indicating its potential as a breakthrough therapeutic method.

Furthermore, the incorporation of liquid biopsies into standard clinical practice has given a non-invasive way for tracking disease progression and response to medication. This technique has the benefit of real-time molecular change evaluation, allowing for more dynamic and rapid therapy modifications.

Continued study into the causes of treatment resistance and recurrence in AML is critical for overcoming present therapeutic limits. Understanding these pathways has resulted in the creation of combination medicines aimed at increasing effectiveness and reducing resistance. Despite these advances, difficulties remain, such as the need for more biomarker refinement for more exact patient categorisation and the high cost of some of these cutting-edge medicines.

The area of AML is making tremendous progress because to technical and therapeutic advances. The combination of new diagnostic technologies, targeted and immunotherapies, and novel monitoring approaches shows promise for improving patient outcomes and tackling some of the most urgent difficulties in AML therapy. Continued research and clinical trials will be critical in bringing these advancements into general clinical practice and ensuring that they benefit a larger patient group.

CONCLUSION

Cutting-edge advances in molecular biology, genetics, and targeted medicines have dramatically changed the landscape of AML diagnosis and therapy. These advances have not only improved our capacity to identify AML more correctly, [1,2] but also offer more effective and personalised treatment choices, offering fresh hope to patients confronting this tough disease.

ACKNOWLEDGEMENT

We appreciate the participation of contributors in this study.

Funding

The financial source was not involved in the study's design, data collection, analysis, interpretation, or article writing.

Conflict of Interest

The authors state that there are no conflicts of interest associated with the publication of this research.

Ethical approval

Not Required

Declaration

All authors contributed to this article and made significant improvements to the paper. Authors read and approved the final version of the text.

REFERENCES

1. Hartmut Döhner, Elihu Estey, David Grimwade, et al, 2017. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood .129 (4): Pages 424–447. Doi: https://doi.org/10.1182/blood-2016-08-733196.

2. Papaemmanuil E, Gerstung M, Bullinger L, et al, 2016. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med. 374(23), Pages 2209-2221. Doi: 10.1056/NEJMoa1516192.

3. Kottaridis PD, Gale RE, Frew ME, et al, 2001. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 98(6), Pages 1752-1759. Doi: 10.1182/blood. v98.6.1752.

4. Van Dongen JJ, van der Velden VH, Brüggemann M, et al, 2015. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood. 125(26), Pages 3996-4009. Doi: 10.1182/blood-2015-03-580027.

5. McGenity C, Clarke EL, Jennings C, et al, 2024. Artificial intelligence in digital pathology: a systematic review and meta-analysis of diagnostic test accuracy. npj Digit. Med. 7, Pages 114 Doi: https://doi.org/10.1038/s41746-024-01106-8.

6. Bera K, Schalper KA, Rimm DL, et al, 2019. Artificial intelligence in digital pathology - new tools for diagnosis and precision oncology. Nat Rev Clin Oncol. 16(11), Pages 703-715. Doi: 10.1038/s41571-019-0252-y.

7. Stone RM, Mandrekar SJ, Sanford BL, et al, 2017. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med. 377(5), Pages 454-464. Doi:10.1056/NEJMoa1614359

8. DiNardo, C. D., Gail J Roboz et al. 2018. Durable remissions with ivosidenib in idh1-mutated relapsed or refractory aml. The New England Journal of Medicine, 378, Pages 2386-2398. Doi: 10.1056/NEJMoa1716984.

9. Amadori S, Suciu S, Selleslag D, et al, 2016. Gemtuzumab Ozogamicin versus Best Supportive Care in Older Patients with Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. J Clin Oncol. 34(9), Pages 972-979. Doi:10.1200/JCO.2015.64.0060.

10. Brahmer JR, Lacchetti C, Schneider BJ, et al, 2018. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 36(17), Pages 1714-1768. Doi:10.1200/JCO.2017.77.6385.

11. Gill S, Brudno JN, 2021. CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered Questions. Am Soc Clin Oncol Educ Book. 41, Pages 1-20. Doi: 10.1200/EDBK_320085.

12. Dombret H, Seymour JF, Butrym A, et al, 2015. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 126(3), Pages 291-299. Doi: 10.1182/blood-2015-01-621664.

13. O'Donnell MR, Tallman MS, Abboud CN, et al, 2017. Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 15(7), Pages 926-957. Doi:10.6004/jnccn.2017.0116.